High Prevalence of Anti-GD2 Immunotherapy-Associated Ocular Adverse Effects Following Allogeneic HCT for Neuroblastoma.

Furukawa T, Akazawa R, Umeda K, Nishio S, Kubota H, Saida S, Kato I, Ueda-Arakawa N, Okamoto T, Fukao D, Sakaguchi K, Takita J

Open source

DOI: 10.1097/mph.0000000000003293
Published: 2026 Nov 1
Container: Journal of pediatric hematology/oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/mph.0000000000003293,
  title = {High Prevalence of Anti-GD2 Immunotherapy-Associated Ocular Adverse Effects Following Allogeneic HCT for Neuroblastoma.},
  author = {Furukawa T and Akazawa R and Umeda K and Nishio S and Kubota H and Saida S and Kato I and Ueda-Arakawa N and Okamoto T and Fukao D and Sakaguchi K and Takita J},
  year = {2026},
  journal = {Journal of pediatric hematology/oncology},
  doi = {10.1097/mph.0000000000003293},
  url = {https://doi.org/10.1097/mph.0000000000003293}
}

RIS

TY  - JOUR
TI  - High Prevalence of Anti-GD2 Immunotherapy-Associated Ocular Adverse Effects Following Allogeneic HCT for Neuroblastoma.
AU  - Furukawa T
AU  - Akazawa R
AU  - Umeda K
AU  - Nishio S
AU  - Kubota H
AU  - Saida S
AU  - Kato I
AU  - Ueda-Arakawa N
AU  - Okamoto T
AU  - Fukao D
AU  - Sakaguchi K
AU  - Takita J
PY  - 2026
JO  - Journal of pediatric hematology/oncology
DO  - 10.1097/mph.0000000000003293
UR  - https://doi.org/10.1097/mph.0000000000003293
ER  -

APA

T, F., R, A., K, U., S, N., H, K., S, S., I, K., N, U., T, O., D, F., K, S., & J, T. (2026). High Prevalence of Anti-GD2 Immunotherapy-Associated Ocular Adverse Effects Following Allogeneic HCT for Neuroblastoma.. Journal of pediatric hematology/oncology. https://doi.org/10.1097/mph.0000000000003293

Source records

pubmed · retrieved 2026-11-10T20:11:11.174Z